Cambridge Investment Research Advisors
CSBR icon

Cambridge Investment Research Advisors’s Champions Oncology CSBR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70K Hold
12,252
– – ﹤0.01% 3824
2025
Q4 		$85K Hold
12,252
– – ﹤0.01% 3718
2025
Q3 		$79K Hold
12,252
– – ﹤0.01% 3614
2025
Q2 		$90K Hold
12,252
– – ﹤0.01% 3479
2025
Q1 		$106K Hold
12,252
– – ﹤0.01% 3343
2024
Q4 		$105K Hold
12,252
– – ﹤0.01% 3321
2024
Q3 		$60K Hold
12,252
– – ﹤0.01% 3319
2024
Q2 		$63K Hold
12,252
– – ﹤0.01% 3202
2024
Q1 		$60K Buy
+12,252
New +$71.7K ﹤0.01% 3198

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors's CSBR Position: Q1 2026 in Review

Cambridge Investment Research Advisors held its Champions Oncology (CSBR) position steady in Q1 2026 at 12,252 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

Cambridge Investment Research Advisors first reported a position in CSBR in Q1 2024 and has held it in 9 quarters since. The position peaked at $106K in Q1 2025. 25 funds tracked by Wall St. Rank hold CSBR as of Q1 2026.

  • Cambridge Investment Research Advisors held 12,252 shares of Champions Oncology worth $70K as of Q1 2026.
  • Cambridge Investment Research Advisors left its Champions Oncology share count unchanged in Q1 2026.
  • Champions Oncology made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #3824 holding.
  • Cambridge Investment Research Advisors first reported a position in Champions Oncology in Q1 2024 and has held it in 9 quarters since.
  • Cambridge Investment Research Advisors's Champions Oncology position peaked at $106K in Q1 2025.
  • 25 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.